Compare Agilent Technologies Inc (A) vs Quantumscape Corp (QS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Quantumscape Corp — how do they compare? Agilent Technologies Inc trades at $128.83 (market cap $37.04B), while Quantumscape Corp trades at $6.55 (market cap $4.18B). The key difference: Agilent Technologies Inc is far larger — about 8.9× Quantumscape Corp's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| A | QS | |
|---|---|---|
Market Cap | $37.04B | $4.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $18.44 |
52-Week Low | $110.24 | $5.96 |
Enterprise Value | $38.59B | $3.34B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
QuantumScape trades at $6.79, down 3.96% today, reflecting ongoing investor caution amid its pre-revenue development stage. The stock shows a bearish technical trend with negative cash flows and significant losses, though recent news of a joint research agreement with Honda (June 18, 2026) provides optimism for its solid-state battery technology. Analyst consensus is heavily weighted toward Hold (72.73%) with no Buy ratings, indicating skepticism about near-term commercialization prospects.
The outlook remains high-risk with substantial execution hurdles in battery development and commercialization. While partnerships like Honda offer long-term potential, persistent negative profitability and cash burn pose significant challenges. Investors should weigh the speculative nature against potential disruptive upside in the evolving EV battery market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
